#China #Minimally Invasive #Weihai #VEMERIX #Weihai Medison

Weihai Medison Unveils VEMERIX: A New Era in Minimally Invasive Surgery

On May 28, 2026, Weihai Medison Medical Equipment Co., Ltd., a renowned Chinese medical-device manufacturer, proudly introduced its latest innovation, VEMERIX. This new international brand is designed as a comprehensive platform for minimally invasive surgery, emphasizing three critical areas: urology, vascular surgery, and perioperative care.

Founded in 2003 in Shandong Province, Weihai Medison has extensive experience and expertise in the medical device industry. VEMERIX is the result of their collaboration with prominent academic institutions in Korea, including Seoul National University and Yonsei University, facilitated through the Medison Korea Joint Research Institute. This partnership injects a wealth of research and technical knowledge into the brand's offerings.

A Focused Portfolio of Innovative Solutions

VEMERIX consolidates several of Medison's NMPA-registered devices into a streamlined portfolio, catering specifically to its target specialties. In urology, the brand presents a disposable circumcision device platform, which includes five NMPA-registered items. Among these is the CE-marked Auto-Circumcision Ring, specifically designed for high-efficiency outpatient surgeries.

Regarding vascular surgery, VEMERIX boasts an advanced 1470 nm endovenous laser energy platform, built around Medison’s single-use medical laser fiber, which meets the performance standards of leading international devices. This innovation marks a significant leap in varicose vein treatment technology.

In the perioperative realm, VEMERIX includes a Medical Vacuum NPWT Pump, along with a registered Scar Gel and a hypochlorous-acid based disinfectant series. These product lines highlight the brand’s commitment to enhancing patient care through innovative medical solutions.

Collaboration with Leading Research Institutions

The backbone of the VEMERIX platform is the collaborative research conducted at the Medison Korea Joint Research Institute, which consists of a multidisciplinary team with senior PhD researchers from prestigious universities. This institute focuses on several advanced medical topics, including urology, vascular interventions, wound-care gel formulations, and aesthetic medicine applications. Their cutting-edge research supports the development of VEMERIX's product lines.

In a statement, Lily (Lianhua) Nan, the founder of Weihai Medison, emphasized the significance of VEMERIX: “This launch marks our introduction to the global medical community. After two decades of providing RD and manufacturing for other brands, we’re leveraging our more than 30 years of experience in laser technology, NPWT, and biopreparations.”

Enhanced Product Offerings and Commitments

Beyond its key product lines, VEMERIX has also introduced a Sterile Single-Use Injection Needle, classified as NMPA Class III, alongside a syringe-assisted injector device tailored for aesthetic and hydrofacial procedures. Medison maintains a portfolio that spans multiple medical device classes and aims to expand its laser fiber applications to various clinical indications beyond its current specialties.

Manufactured in a state-of-the-art 2,000-square-meter facility that operates Class-100K cleanrooms, Medison fulfills strict quality standards. The company holds multiple certifications, including ISO 9001 and ISO 13485, signifying their dedication to manufacturing excellence.

VEMERIX is not just a product; it represents the culmination of decades' worth of research, innovation, and partnerships within the medical field. With products already distributed across six continents, including North America, South America, Europe, the Middle East, and Asia, VEMERIX is poised to become a leading name in minimally invasive surgical solutions worldwide.

Interested parties can explore the comprehensive product catalog and request samples via the official VEMERIX website, paving the way for future collaborations in healthcare innovation.